|
Gene: DDIT4 |
Gene summary for DDIT4 |
Gene summary. |
Gene information | Species | Human | Gene symbol | DDIT4 | Gene ID | 54541 |
Gene name | DNA damage inducible transcript 4 | |
Gene Alias | Dig2 | |
Cytomap | 10q22.1 | |
Gene Type | protein-coding | GO ID | GO:0001666 | UniProtAcc | A0A024QZQ6 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
54541 | DDIT4 | GSM4909280 | Human | Breast | Precancer | 1.97e-02 | 4.15e-01 | 0.0305 |
54541 | DDIT4 | GSM4909281 | Human | Breast | IDC | 2.45e-02 | 1.64e-01 | 0.21 |
54541 | DDIT4 | GSM4909282 | Human | Breast | IDC | 6.52e-116 | 1.38e+00 | -0.0288 |
54541 | DDIT4 | GSM4909285 | Human | Breast | IDC | 6.72e-06 | 2.96e-01 | 0.21 |
54541 | DDIT4 | GSM4909286 | Human | Breast | IDC | 4.76e-03 | -5.78e-04 | 0.1081 |
54541 | DDIT4 | GSM4909288 | Human | Breast | IDC | 2.29e-04 | -5.88e-01 | 0.0988 |
54541 | DDIT4 | GSM4909291 | Human | Breast | IDC | 4.04e-04 | -4.86e-01 | 0.1753 |
54541 | DDIT4 | GSM4909293 | Human | Breast | IDC | 8.23e-03 | -3.12e-01 | 0.1581 |
54541 | DDIT4 | GSM4909294 | Human | Breast | IDC | 1.48e-05 | -3.46e-01 | 0.2022 |
54541 | DDIT4 | GSM4909297 | Human | Breast | IDC | 1.67e-06 | -3.11e-01 | 0.1517 |
54541 | DDIT4 | GSM4909298 | Human | Breast | IDC | 6.13e-12 | -5.49e-01 | 0.1551 |
54541 | DDIT4 | GSM4909301 | Human | Breast | IDC | 1.82e-11 | -5.66e-01 | 0.1577 |
54541 | DDIT4 | GSM4909304 | Human | Breast | IDC | 2.17e-04 | 2.53e-01 | 0.1636 |
54541 | DDIT4 | GSM4909307 | Human | Breast | IDC | 1.54e-03 | -4.46e-01 | 0.1569 |
54541 | DDIT4 | GSM4909308 | Human | Breast | IDC | 2.17e-06 | -4.54e-01 | 0.158 |
54541 | DDIT4 | GSM4909311 | Human | Breast | IDC | 6.87e-21 | -5.95e-01 | 0.1534 |
54541 | DDIT4 | GSM4909312 | Human | Breast | IDC | 3.49e-11 | -4.57e-01 | 0.1552 |
54541 | DDIT4 | GSM4909317 | Human | Breast | IDC | 3.68e-03 | 3.61e-01 | 0.1355 |
54541 | DDIT4 | GSM4909319 | Human | Breast | IDC | 1.50e-29 | -6.07e-01 | 0.1563 |
54541 | DDIT4 | GSM4909320 | Human | Breast | IDC | 3.53e-08 | -6.64e-01 | 0.1575 |
Page: 1 2 3 4 5 6 7 8 9 10 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000913522 | Liver | HCC | purine nucleoside diphosphate metabolic process | 70/7958 | 103/18723 | 1.52e-07 | 2.82e-06 | 70 |
GO:000917922 | Liver | HCC | purine ribonucleoside diphosphate metabolic process | 70/7958 | 103/18723 | 1.52e-07 | 2.82e-06 | 70 |
GO:000913222 | Liver | HCC | nucleoside diphosphate metabolic process | 81/7958 | 124/18723 | 2.34e-07 | 4.17e-06 | 81 |
GO:000610921 | Liver | HCC | regulation of carbohydrate metabolic process | 109/7958 | 178/18723 | 3.36e-07 | 5.78e-06 | 109 |
GO:004693922 | Liver | HCC | nucleotide phosphorylation | 68/7958 | 101/18723 | 3.95e-07 | 6.70e-06 | 68 |
GO:190121412 | Liver | HCC | regulation of neuron death | 179/7958 | 319/18723 | 5.65e-07 | 9.01e-06 | 179 |
GO:000616522 | Liver | HCC | nucleoside diphosphate phosphorylation | 66/7958 | 99/18723 | 1.01e-06 | 1.52e-05 | 66 |
GO:000166612 | Liver | HCC | response to hypoxia | 172/7958 | 307/18723 | 1.06e-06 | 1.59e-05 | 172 |
GO:000609622 | Liver | HCC | glycolytic process | 56/7958 | 81/18723 | 1.11e-06 | 1.65e-05 | 56 |
GO:00516071 | Liver | HCC | defense response to virus | 151/7958 | 265/18723 | 1.27e-06 | 1.85e-05 | 151 |
GO:01405461 | Liver | HCC | defense response to symbiont | 151/7958 | 265/18723 | 1.27e-06 | 1.85e-05 | 151 |
GO:003629312 | Liver | HCC | response to decreased oxygen levels | 179/7958 | 322/18723 | 1.29e-06 | 1.87e-05 | 179 |
GO:007048212 | Liver | HCC | response to oxygen levels | 191/7958 | 347/18723 | 1.42e-06 | 2.03e-05 | 191 |
GO:000675722 | Liver | HCC | ATP generation from ADP | 56/7958 | 82/18723 | 2.06e-06 | 2.83e-05 | 56 |
GO:005138421 | Liver | HCC | response to glucocorticoid | 90/7958 | 148/18723 | 5.18e-06 | 6.47e-05 | 90 |
GO:00319291 | Liver | HCC | TOR signaling | 78/7958 | 126/18723 | 8.49e-06 | 9.97e-05 | 78 |
GO:00106752 | Liver | HCC | regulation of cellular carbohydrate metabolic process | 88/7958 | 146/18723 | 1.08e-05 | 1.24e-04 | 88 |
GO:007233212 | Liver | HCC | intrinsic apoptotic signaling pathway by p53 class mediator | 51/7958 | 76/18723 | 1.27e-05 | 1.42e-04 | 51 |
GO:00715482 | Liver | HCC | response to dexamethasone | 30/7958 | 39/18723 | 1.28e-05 | 1.43e-04 | 30 |
GO:190121612 | Liver | HCC | positive regulation of neuron death | 62/7958 | 97/18723 | 1.67e-05 | 1.81e-04 | 62 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0414010 | Esophagus | ESCC | Autophagy - animal | 101/4205 | 141/8465 | 7.60e-08 | 6.21e-07 | 3.18e-07 | 101 |
hsa041505 | Esophagus | ESCC | mTOR signaling pathway | 98/4205 | 156/8465 | 5.81e-04 | 1.95e-03 | 9.97e-04 | 98 |
hsa041517 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
hsa0414015 | Esophagus | ESCC | Autophagy - animal | 101/4205 | 141/8465 | 7.60e-08 | 6.21e-07 | 3.18e-07 | 101 |
hsa0415013 | Esophagus | ESCC | mTOR signaling pathway | 98/4205 | 156/8465 | 5.81e-04 | 1.95e-03 | 9.97e-04 | 98 |
hsa0415114 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
hsa041406 | Liver | Cirrhotic | Autophagy - animal | 65/2530 | 141/8465 | 3.10e-05 | 2.47e-04 | 1.52e-04 | 65 |
hsa0414011 | Liver | Cirrhotic | Autophagy - animal | 65/2530 | 141/8465 | 3.10e-05 | 2.47e-04 | 1.52e-04 | 65 |
hsa0414021 | Liver | HCC | Autophagy - animal | 99/4020 | 141/8465 | 3.08e-08 | 4.70e-07 | 2.61e-07 | 99 |
hsa041502 | Liver | HCC | mTOR signaling pathway | 95/4020 | 156/8465 | 4.70e-04 | 1.99e-03 | 1.11e-03 | 95 |
hsa0414031 | Liver | HCC | Autophagy - animal | 99/4020 | 141/8465 | 3.08e-08 | 4.70e-07 | 2.61e-07 | 99 |
hsa0415011 | Liver | HCC | mTOR signaling pathway | 95/4020 | 156/8465 | 4.70e-04 | 1.99e-03 | 1.11e-03 | 95 |
hsa041514 | Lung | IAC | PI3K-Akt signaling pathway | 60/1053 | 354/8465 | 7.03e-03 | 2.86e-02 | 1.90e-02 | 60 |
hsa041407 | Lung | IAC | Autophagy - animal | 28/1053 | 141/8465 | 7.64e-03 | 3.03e-02 | 2.01e-02 | 28 |
hsa0415111 | Lung | IAC | PI3K-Akt signaling pathway | 60/1053 | 354/8465 | 7.03e-03 | 2.86e-02 | 1.90e-02 | 60 |
hsa0414012 | Lung | IAC | Autophagy - animal | 28/1053 | 141/8465 | 7.64e-03 | 3.03e-02 | 2.01e-02 | 28 |
hsa041409 | Oral cavity | OSCC | Autophagy - animal | 94/3704 | 141/8465 | 2.73e-08 | 2.38e-07 | 1.21e-07 | 94 |
hsa041504 | Oral cavity | OSCC | mTOR signaling pathway | 90/3704 | 156/8465 | 2.87e-04 | 9.15e-04 | 4.66e-04 | 90 |
hsa041516 | Oral cavity | OSCC | PI3K-Akt signaling pathway | 185/3704 | 354/8465 | 6.26e-04 | 1.86e-03 | 9.49e-04 | 185 |
hsa0414014 | Oral cavity | OSCC | Autophagy - animal | 94/3704 | 141/8465 | 2.73e-08 | 2.38e-07 | 1.21e-07 | 94 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DDIT4 | insertion | Frame_Shift_Ins | novel | c.133_134insCATTCAA | p.Arg45ProfsTer44 | p.R45Pfs*44 | Q9NX09 | protein_coding | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD | ||
DDIT4 | insertion | Frame_Shift_Ins | novel | c.135_136insGGCAGGACGCACTTGTC | p.Ser46GlyfsTer57 | p.S46Gfs*57 | Q9NX09 | protein_coding | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD | ||
DDIT4 | deletion | Frame_Shift_Del | novel | c.86delC | p.Pro29ArgfsTer68 | p.P29Rfs*68 | Q9NX09 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
DDIT4 | SNV | Missense_Mutation | c.79G>C | p.Asp27His | p.D27H | Q9NX09 | protein_coding | tolerated(0.07) | benign(0.092) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
DDIT4 | SNV | Missense_Mutation | novel | c.89N>T | p.Pro30Leu | p.P30L | Q9NX09 | protein_coding | tolerated(0.14) | benign(0) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DDIT4 | SNV | Missense_Mutation | c.272N>G | p.His91Arg | p.H91R | Q9NX09 | protein_coding | tolerated(0.34) | benign(0.001) | TCGA-AP-A0LD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
DDIT4 | SNV | Missense_Mutation | rs776692483 | c.47N>T | p.Ser16Leu | p.S16L | Q9NX09 | protein_coding | tolerated(0.52) | benign(0.277) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
DDIT4 | SNV | Missense_Mutation | c.427N>T | p.Arg143Trp | p.R143W | Q9NX09 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-B5-A0JR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
DDIT4 | SNV | Missense_Mutation | novel | c.503G>A | p.Ser168Asn | p.S168N | Q9NX09 | protein_coding | tolerated(0.44) | possibly_damaging(0.696) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DDIT4 | SNV | Missense_Mutation | novel | c.431G>A | p.Gly144Glu | p.G144E | Q9NX09 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
54541 | DDIT4 | NA | PF-04523655 |
Page: 1 |